Australia’s most read investor-focused magazine for ASX-listed Tech & Biotech stocks

Pacific Edge has delivered a modest but important improvement in fourth quarter test volumes, with total laboratory throughput rising 2.7% from the previous quarter to 5,582 tests. That is hardly champagne-cork territory, but it does matter because the gain came while the company was juggling a transition away from Cxbladder Detect, selling into a US market where Medicare still does not reimburse key products, and running with a leaner sales team after cost-saving measures.

The mix of growth was also telling. US volumes rose 1.0% to 4,064 tests, with Kaiser Permanente Southern California doing much of the heavy lifting, while Asia Pacific volumes climbed 7.7% to 1,518. Even so, the broader picture remains one of a business still rebuilding from the setback of Medicare non-coverage. Volumes are improving sequentially, but they remain well below the levels Pacific Edge was reporting a year earlier. For investors, that underlines a central point - the immediate story is less about booming sales and more about whether reimbursement and policy settings are finally turning in the company’s favour.

Medicare could be the circuit breaker

That is where the latest progress with Novitas becomes crucial. Pacific Edge says the February Contractor Advisory Committee hearing delivered strong support from expert clinicians for urine-based biomarkers in hematuria assessment, including the role of Cxbladder Triage and Triage Plus. The company believes Novitas now has the information needed to produce a draft local coverage determination by the end of September 2026, with final effective coverage potentially following about six months later.

Investors should not confuse that with money in the bank just yet. Draft policy is not final policy, and final policy is not the same as instant revenue acceleration. Still, this is the clearest sign yet that the Medicare door may be reopening. Chief executive Dr Peter Meintjes described the company as being "on the cusp of a major commercial inflection point", which is management shorthand for saying the next big swing factor is no longer test performance, but payment.

If Pacific Edge can secure positive Medicare coverage, the effect could stretch well beyond the federal payer system. Medicare recognition often acts as a quality stamp for the broader market, particularly in diagnostics, where clinicians, hospitals and private insurers tend to take their cues from formal coverage decisions.

Commercial payers are starting to move

That read-through is already emerging in the private market. Cxbladder Triage has now won coverage from Blue Cross Blue Shield of North Carolina and South Carolina, representing about 4.2 million covered lives combined, while Highmark has adopted policy for Cxbladder Monitor across its 7 million covered lives. Together, those wins take Pacific Edge’s newly addressed commercial population to 11.2 million people.

The significance is not just the numbers. These policies mirror language published by Avalon Healthcare Systems, suggesting third-party policy support can influence insurer adoption. That matters because Pacific Edge is effectively building a commercial reimbursement template one payer at a time. The company has also been explicit that policy adoption is the first step, with contracting and pricing still needed before the full revenue benefit shows through. In plain English, policy wins are encouraging, but investors should watch average selling prices and reimbursement receipts before declaring victory.

Encouragingly, the company says these commercial payers cover more than twice the patient population reached through Kaiser Permanente Southern California. That suggests the addressable market is widening, even if the revenue conversion will take time.

APAC progress adds another string to the bow

Pacific Edge also notched meaningful wins closer to home. Singapore General Hospital will incorporate Triage, Triage Plus and Monitor into patient care, while Townsville University Hospital has begun clinical use of Triage Plus and Monitor. These are strategically useful additions because they show the products gaining traction in real clinical pathways, not just in trial settings or sales decks.

The Townsville adoption is particularly interesting operationally, with nurses leading test ordering under a consultant-backed protocol. That hints at workflow advantages that could support broader adoption, especially in regional settings where specialist access is more limited.

Meanwhile, Pacific Edge has filed a Patent Cooperation Treaty application for Triage Plus, covering its multi-modal approach combining DNA single nucleotide variants with existing mRNA biomarkers and algorithmic analysis. That does not create immediate earnings, but it helps reinforce the moat around the next generation of the platform.

What investors should watch now

The next chapter is fairly clear. Investors should track three things: whether Novitas publishes a positive draft Medicare policy by September, whether commercial payer wins translate into better pricing and reimbursement, and whether clinical evidence continues to strengthen adoption. On that last point, the AUSSIE study’s preliminary data won Best Oncology Presentation at the USANZ conference, giving Pacific Edge another credibility tick with clinicians.

For now, Pacific Edge remains a policy-driven diagnostics story rather than a straight volume-growth tale. The fourth quarter numbers suggest the business is steadying. The real test is whether reimbursement momentum finally turns scientific promise into commercial traction.

InFocus Group Holdings has given investors their clearest look yet at what it is trying to build in iGaming, unveiling a global technical preview of its in-house sweepstakes casino platform, Codexa. For a company better known for data analytics and software services, the move is more than a product launch - it is an attempt to show the market that Codexa is real, working and potentially valuable as either a licensing business or an asset that could attract a buyer.

The preview, accessible through a white-label deployment called Gold Ante, is now live and publicly viewable for the first time. That matters because IFG is no longer asking investors to back a concept on trust alone. It is putting the platform in front of prospective clients, acquirers and the broader market as proof that the technology exists and can be demonstrated in a live setting.

What has actually launched - and what has not

The key nuance is that this is still a preview rather than a full commercial roll-out. Full platform functionality is available in the United States as a showcase environment, while international users can access selected game content depending on geographic restrictions imposed by third-party providers. Commercial sweepstakes features such as Gold Coin purchasing and prize redemption are not yet active, with a limited US commercial launch slated for later this month.

That distinction is important for investors. A live demo is useful, but it is not the same as proven monetisation. IFG is effectively at the stage of demonstrating technical readiness and product breadth, while commercial validation is still ahead. The company also says the preview contains only about 20% of the full game catalogue planned for launch, with more content and provider integrations to follow.

In other words, the market now has evidence that Codexa is built. What it does not yet have is evidence of material customer uptake, recurring revenue or operating metrics.

Why Codexa could matter

Management is pitching Codexa as an institutional-grade platform built for scale, with features including blockchain-verified fairness, AI-driven player personalisation, a proprietary random number generator and cloud-native microservices architecture. In plain English, IFG is arguing that this is not a cut-price gaming website stitched together from off-the-shelf parts, but a serious platform designed to handle high traffic and to be deployed quickly for other operators.

That claim sits at the heart of the investment case. If Codexa can be licensed to third parties under a white-label and managed services model, IFG could build a higher-margin, recurring revenue stream than investors might expect from a typical small-cap software contractor. The company is also keeping a second option on the table - an outright sale of the platform or even the IFG iGaming business unit.

That dual-track strategy gives the story some speculative appeal. A licensing model offers the promise of ongoing annuity-style income, while a sale would be a cleaner and potentially quicker route to crystallising value. Of course, both paths depend on outside parties seeing enough merit in the platform to sign a contract or write a cheque.

The market opportunity sounds large - but execution is everything

IFG is targeting the US sweepstakes casino market, which it says generated about US$3.4 billion in net operator revenue in 2024, based on KPMG data. It also cites more than US$10 billion in player spend, framing the sector as a rapidly growing corner of online gaming.

Those are hefty numbers for a company of IFG’s size, and they help explain why management has made this strategic pivot. Even a modest foothold in that market could be meaningful relative to IFG’s existing base. The company also argues that there are limited global platforms offering comparable technology, suggesting a supply gap for proven, compliant and scalable sweepstakes infrastructure.

Still, large addressable markets have lured many hopefuls before. Investors should keep in mind that being present in an attractive sector is not the same thing as capturing share. The real test will be whether Codexa can win operators, convert interest into revenue and navigate the compliance and content-partner hurdles that come with serving the North American market.

What management is signalling

Chief executive Ken Tovich described the preview as a significant milestone and said the launch allows prospective clients and acquirers to experience the platform firsthand. That wording is worth noting. Management is not talking only about attracting players - it is clearly talking to counterparties that might licence or buy the technology.

That is probably the most investor-relevant takeaway from the release. IFG wants the market to view Codexa not merely as a speculative gaming venture, but as a potentially saleable software asset. The limited US commercial launch planned for later this month appears designed not only to test revenue generation, but also to help prove the platform’s commercial potential to would-be partners and buyers.

The bottom line for shareholders

This is a meaningful step forward because IFG has moved from promise to prototype in public view. Codexa is live, management has outlined two commercial pathways, and the company is aiming at a market that is undeniably large. Yet the leap from technical preview to shareholder value remains just that - a leap.

For now, Codexa gives IFG a more interesting story and possibly a more valuable strategic asset. Whether it becomes a genuine earnings driver, or simply a well-dressed demo, will depend on what happens next in the US launch and in discussions with clients and potential acquirers. For investors, the platform is now on the table. The harder part is seeing whether anyone else wants to play.

Memphasys (ASX: MEM) is attempting something many ASX biotechs promise but few deliver: a clean pivot from scientific validation to commercial execution. The company’s narrative has shifted decisively away from proving the science and towards proving the business model.

As director Marjan Mikel put it bluntly, the shift has been deliberate and recent: “we made [the strategy] very public in around about September, October of last year… to focus solely and wholly on the commercialisation” .

At the centre of the story is the Felix™ system, a sperm separation device that replaces decades-old centrifugation methods. The company positions it as the first meaningful advance in andrology workflows in over 40 years, combining electrophoresis and filtration to produce higher-quality sperm samples in roughly six minutes, versus up to 45 minutes using traditional methods .

That speed is not just a clinical curiosity - it is the economic hook.

The real product: cartridges, not consoles

From a commercial perspective, the real product is not the machine but the consumable cartridge. Each IVF or ICSI cycle requires one cartridge, turning every procedure into a revenue event.

Mikel is explicit about this distinction: “our business model is not selling a device… it’s selling a new sperm separation technique that requires a Felix cartridge to be used every single time” .

This “razor-and-blade” model is well-worn territory in medtech, but Memphasys is only now beginning to prove it works in practice.

The March quarter appears to mark a turning point. Revenue reached roughly $111,000 across multiple regions, including Japan, Europe and the Middle East, representing the first meaningful multi-market contribution .

More telling than the headline number is what sits underneath. As Mikel noted: “we are getting repeat orders from existing clients… which is where our business model is built” .

From trial to workflow adoption

That distinction matters. Early-stage medtech stories often stall at the “trial phase”, where promising technology fails to embed into everyday workflows. Memphasys is arguing that hurdle has been cleared.

Clinics are not just testing Felix; they are incorporating it into standard operating procedures. In Mikel’s words: “we are getting involved in the workflows of these organisations… and that’s really important” .

The company’s commercial strategy has been reset accordingly. Gone is the diffuse R&D focus; in its place is a tightly defined go-to-market approach centred on direct engagement with IVF clinics and carefully selected partners.

Management has explicitly rejected traditional catalogue-style distribution. As Mikel put it: “you just can’t put it on a catalogue and expect it to sell itself” .

Why clinics are buying in

The pitch to clinics is straightforward and commercially grounded. Felix reduces sperm preparation time from around 45 minutes to approximately six minutes, standardises outcomes and improves lab throughput.

In IVF labs, time quite literally is money. Faster processing means more procedures per day, which directly boosts clinic revenue.

Mikel leans heavily on simplicity as the killer feature: “this is how easy it is… press button. That’s it” . He adds that even non-specialists can operate the system: “someone as dumb as me could do this… that’s how easy it is” .

The simplicity is not just anecdotal. As shown in the process diagram on page 12, the workflow is reduced to a handful of steps before activation, reinforcing how easily it integrates into lab routines .

Europe and MENA: where the growth lies

Geographically, Europe and MENA are the primary battlegrounds. Europe alone accounts for around one million IVF cycles annually, and the recently secured CE mark opens that market in full.

The company has already secured contracts in both regions and is seeing repeat demand. Mikel highlighted the significance of this early traction: “we’ve got contracts… and importantly, we are getting repeat orders” .

Japan provides a useful proof-of-concept market with ongoing repeat orders, but it is not the immediate focus. India, pending regulatory approval, represents a near-term expansion opportunity, while Australia and New Zealand are positioned as the next step following TGA approval.

The numbers start to stack up

The economics begin to look compelling when scaled. Management is targeting cartridge pricing of $80 to $150, with cost of goods below $40, implying gross margins above 60% .

Each clinic is expected to generate between $100,000 and $300,000 in annual revenue, depending on procedure volumes.

Mikel frames the model in simple, cumulative terms: “every single client builds on the previous clients… it’s a recurring revenue stream” .

This is where the leverage lies. Each new clinic does not replace revenue - it stacks on top of it.

Scaling brings its own challenges

Of course, early commercialisation is rarely smooth. Revenue remains somewhat lumpy as orders are shipped in batches, and scaling manufacturing to meet demand will require capital.

In fact, demand may already be testing capacity. Mikel was unusually candid on this point: “we are going to have to raise capital… because we’re selling too much Felix” .

That funding, however, is framed as growth capital rather than survival capital, with options ranging from debt to order-backed financing.

A large and growing market backdrop

The broader market backdrop is supportive. Global fertility rates are declining, and assisted reproductive technologies are a growing industry, forecast to expand significantly over the next decade .

Male infertility accounts for a substantial portion of cases, and the lack of innovation in sperm preparation techniques provides a clear opening for disruption.

As Mikel summarised: “there is no shortage of opportunity… every cycle is more revenue for us” .

The inflection point

Memphasys now sits at an inflection point rather than a destination. The technology case appears largely settled; the commercial case is just beginning to take shape.

The key question is whether early signs - repeat orders, multi-market revenue and contracted agreements - translate into sustained, scalable growth.

Mikel’s definition of success is tellingly operational: “broadening the number of clients… and making sure that they are reordering Felix on a regular basis” .

If that plays out, the story shifts from speculative biotech to a medtech platform with annuity-style revenues. If not, it risks joining the long list of promising technologies that never quite made the leap from lab bench to balance sheet.

Imricor Medical Systems has taken another step in its US rollout, lodging its NorthStar Mapping System with the FDA for a pediatric label expansion via the Special 510(k) pathway. For investors, the key point is not just the filing itself, but what it says about the company’s commercial playbook: get NorthStar into receptive hospitals early, build an installed base, and use that foothold to support the broader launch of its full electrophysiology platform in the world’s biggest healthcare market.

A logical follow-up to January’s adult clearance

The move follows NorthStar’s FDA clearance for adult patients in January 2026, so this is not a standing-start regulatory event. Rather, it looks like an extension of a strategy already under way. Imricor is trying to convert regulatory progress into actual hospital adoption, and the pediatric segment appears to be one of the first commercial doors it believes it can push open.

That matters because small medtech companies often win by sequencing their markets carefully. Instead of waiting for broad-based adoption across adult hospitals, Imricor is targeting areas where the product’s value proposition may be especially compelling. In this case, that means children’s hospitals, where reducing radiation exposure is likely to resonate strongly with clinicians and administrators alike.

Why pediatrics could be more than a niche

Imricor says there are more than 250 children’s hospitals in the United States and that it has already received inbound interest from that customer group following the adult clearance. That is an encouraging detail because it suggests demand discovery is already happening without the company having to spend heavily to manufacture it. Hospitals are making the running, or at least picking up the phone.

The pediatric angle also appears commercially attractive for another reason. NorthStar is used in interventional cardiovascular magnetic resonance procedures, and Imricor argues it may improve workflows that are currently performed using standard MRI system interfaces alone. If that proves true in practice, the product is not merely a regulatory novelty but a tool that could make an existing clinical process more usable and more efficient. Investors should always pay attention when a device company can point to workflow improvement, because hospitals do not buy technology simply because it is clever. They buy it when it solves a problem.

Building revenue before the full platform lands

One of the more interesting aspects of the update is that management frames pediatrics as an early commercial channel ahead of broader US adoption of the full EP platform in adult hospitals. In plain English, Imricor is trying to create revenue opportunities and clinical reference sites now, rather than waiting for the whole strategic puzzle to be completed.

That matters because installed base tends to be one of the most valuable currencies in medtech. Once a hospital adopts a system, trains staff and develops familiarity with its use, the odds improve that further products from the same ecosystem can follow. Imricor is effectively trying to seed the market. A handful of pediatric wins could do more than add sales - they could provide proof points, physician advocates and operational learnings for a wider US expansion.

The company also notes it can already sell NorthStar to children’s hospitals that have proactively contacted it. The label expansion, if cleared, would allow it to market proactively into that segment rather than waiting for inbound interest. That is a meaningful distinction. Passive demand is useful; active selling is better.

Timing, momentum and the next watchpoint

Imricor expects clearance in the current quarter. That gives the market a near-term catalyst to watch. The real test, though, will not be the filing or even the clearance alone. Investors will want to see whether regulatory progress converts into orders, placements, and eventually recurring procedure-related revenue.

Chief executive Steve Wedan said the submission was an “exciting and practical step” to accelerate US commercialisation and argued that pediatric centres could become an important adoption channel. He also used the update to underline a broader strategic message: Imricor does not want to be seen solely as an iCMR ablation company, but as a wider interventional MR business.

That broader framing is important. It suggests NorthStar is not just a single-product story, but part of a larger attempt to establish Imricor in MRI-guided interventional cardiology. For shareholders, that is the attraction and the challenge. The attraction is a potentially differentiated platform in a large market. The challenge is that commercial traction still needs to be demonstrated, one hospital at a time.

For now, the pediatric filing looks like a sensible and potentially value-accretive move. It broadens the addressable market, sharpens the company’s US commercial narrative, and gives investors a clearer sense of how Imricor intends to turn regulatory wins into real-world adoption.

Pathkey.AI Limited has taken a meaningful step forward in its commercialisation journey, securing a services agreement with Imunexus Therapeutics Limited valued at up to $100,000.

While the contract size is relatively modest, the importance of the deal lies in what it represents. This is a clear shift from development and validation of the technology to actual revenue generation - a key milestone for any emerging AI company.

The agreement includes an upfront payment component, providing immediate revenue, with additional value tied to milestone-based services. Importantly, it establishes a commercial relationship that has the potential to expand over time.

TrialKey Moves into Real-World Use

At the centre of the engagement is Pathkey’s flagship TrialKey platform, which is being embedded into Imunexus’ clinical development and capital raising workflows.

The platform will be applied across a range of high-value use cases, including clinical trial design optimisation, probability of success analysis and benchmarking against global datasets. It will also support investor communications and broader capital markets positioning.

This breadth of application is significant. It highlights that TrialKey is not a single-purpose tool, but rather a platform that can sit across both scientific and commercial functions within a biotech company. That dual capability has the potential to broaden its addressable market.

A Repeatable Commercial Model Emerging

The structure of the engagement provides further insight into how Pathkey intends to scale.

The services are delivered in phases, starting with a pilot and baseline analytics, before moving into deeper clinical integration and ongoing reporting. This approach enables Pathkey to establish an initial foothold, while creating a pathway to expand its role over time.

This “land and expand” model is well understood in technology businesses and, if executed effectively, can lead to recurring revenue and higher lifetime value per client.

Management has indicated that this engagement is intended to serve as a template for future deals, with the potential to replicate the model across additional biotechnology and pharmaceutical clients.

Why This Matters for Investors

For early-stage technology companies, the key inflection point is always commercial validation.

This agreement demonstrates that Pathkey’s technology is not only functional, but also valued by a third-party customer operating in a real-world setting. It provides early evidence that the platform can integrate into existing workflows and deliver practical utility.

Equally important is the potential for scalability. The clinical development sector is large and increasingly data-driven, with a growing need for tools that improve decision-making, reduce risk and enhance efficiency.

Pathkey’s positioning at the intersection of clinical development and capital markets support could prove to be a differentiator as the company builds out its client base.

Outlook

While the financial contribution from this contract is unlikely to be material in the near term, the strategic importance is clear.

The focus now shifts to execution - converting additional clients, expanding existing relationships and demonstrating a pathway to recurring revenue.

If Pathkey can successfully replicate this model across multiple engagements, it may begin to establish the foundations of a scalable AI-driven business. For investors, this marks an early but important step in that journey.